Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s stock price traded down 0.8% on Wednesday . The company traded as low as C$2.51 and last traded at C$2.53. 74,200 shares were traded during trading, a decline of 48% from the average session volume of 141,666 shares. The stock had previously closed at C$2.55.
Cardiol Therapeutics Stock Performance
The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. The company has a market cap of C$174.70 million, a PE ratio of -5.68 and a beta of 0.70. The stock's 50 day simple moving average is C$2.72 and its two-hundred day simple moving average is C$2.84.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
